RLMD News and Press, Relmada Therapeutics Inc. From 12/15/21

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference LLP today announced that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system, in an upsized underwritten public offering. The offerin...

Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option PR Newswire CORAL GABLES, Fla. , Dec. 14, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing d...

Relmada Therapeutics (NASDAQ:RLMD) has priced its upsized public offering of ~8.8M common shares at $17.00/share, for expected gross proceeds of ~$150M. Underwriters' over-allotment is an additional ~1.3M shares. Net proceeds will be used to fund R&D activities for clinical development pr...

Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock PR Newswire CORAL GABLES, Fla. , Dec. 8, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central ne...

Gainers: Arhaus (NASDAQ:ARHS) +6%. Radware (NASDAQ:RDWR) +5%. Liquidity Services (NASDAQ:LQDT) +5%. Digital World Acquisition (NASDAQ:DWAC) +3%. Big 5 Sporting Goods (NASDAQ:BGFV) +26%. Losers: Lucid Group (NASDAQ:LCID) -8%. Relmada Therapeutics (NASDAQ:RLMD) -7%. VectivBio Holding AG (NASDAQ...

Relmada Therapeutics (NASDAQ:RLMD) has lost ~10.2% in the post-market after the company announced an underwritten public offering of $100M worth of its common stock. A 30-day option allowing underwriters to purchase on the same terms and conditions up to an additional 15% of th...

Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology PR Newswire CORAL GABLES, Fla. , Dec. 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology compan...

Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market. The pandemic is predicted to have a long and short term im...

Relmada Therapeutics, Inc. (RLMD) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO & Director Maged Shenouda - Chief Financial Officer Charles Ence - Chief Accounting & Compliance Officer Conferenc...

Relmada Therapeutics (NASDAQ:RLMD): Q3 GAAP EPS of -$2.44 misses by $0.84. Press Release As of September 30, 2021, the Company had cash and short-term investments of $88.1 million, compared to cash, cash equivalents, and short-term investments of approximately $117.1 million at December 31, 2...